Ask AI
ProCE Banner Activity

Subcutaneous Administration of Immune Checkpoint Inhibitors for Solid Tumors

Clinical Thought

In this commentary, oncology experts discuss recent approvals of subcutaneous (SC) formulations of immune checkpoint inhibitors for solid tumors, representing major potential for saving time and resources and improving patient quality of life.

Released: June 09, 2026

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by an educational grant from Merck Sharp & Dohme LLC.

Merck Sharp & Dohme, LLC

Target Audience

This program is intended for physicians, nurse practitioners, nurse navigators, physician associates, nurses, and pharmacists who care for patients with solid tumors.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Determine optimal immunotherapy strategies based on clinical experience, expert perspectives, and consensus guidelines for patients with solid tumors

  • Identify, assess, and manage immune-related adverse events in patients with solid tumors receiving ICI monotherapy or ICI-based combination regimens

  • Select optimal ICI-based treatment strategies for patients in special populations, such as squamous histology, liver disease, and CNS metastases

  • Actively engage patients receiving ICI-based therapy in their treatment plan

Disclosure

Primary Author

Patrick Forde, MD, PhD: researcher: AstraZeneca, BioNTech, Bristol Myers Squibb, Regeneron, Summit; consultant/advisor/speaker: Amgen, AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Flame, Fosun, F-Star, G1, Genentech, Iteos, Janssen, Novartis, Regeneron, Sanofi.

Zev A. Wainberg, MD: consultant/advisor/speaker: AbbVie, Alligator, Amgen, AstraZeneca, Bristol Myers Squibb, Ipsen, Janssen, Lilly, Merck, Merck KGA, Revolution Medicine.